An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Bronchodilators are essential therapeutic agents indicated for patients with lower-than-optimal airflow through the lungs due to obstructive airway conditions. The primary classes include beta-2 agonists and anticholinergic agents, both of which act on the smooth muscle of the bronchioles to facilitate airway dilation. These medications are widely used in the management of asthma and chronic obstructive pulmonary disease, either to rapidly reverse acute symptoms or to improve baseline lung function in chronic disease.
Perez-Padilla R, Menezes AMB. Chronic Obstructive Pulmonary Disease in Latin America. Ann Glob Health. 2019 Jan 22;85(1)
-
PMC
-
PubMed
Almeshari MA, Alobaidi NY, Sapey E, Usmani O, Stockley RA, Stockley JA. Small Airways Response to Bronchodilators in Adults with Asthma or COPD: A Systematic Review. Int J Chron Obstruct Pulmon Dis. 2021;16:3065-3082.
-
PMC
-
PubMed
Pleasants RA, Wang T, Gao J, Tang H, Donohue JF. Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis. Drugs. 2016 Mar;76(3):343-61.
-
PubMed
Heo YA. Revefenacin: First Global Approval. Drugs. 2019 Jan;79(1):85-91.
-
PMC
-
PubMed
LeMaster WB, Witenko CJ, Lacy MK, Olmsted AW, Moran EJ, Mahler DA. Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPD. Int J Chron Obstruct Pulmon Dis. 2024;19:2299-2308.
-
PMC
-
PubMed
